AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback